Psyence Biomedical (Psyence Biomedical) Treasury Stock : $0.00 Mil (As of Mar. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Psyence Biomedical's treasury stock for the quarter that ended in Mar. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Psyence Biomedical Treasury Stock Historical Data

The historical data trend for Psyence Biomedical's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Treasury Stock Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Treasury Stock

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Mar23
Treasury Stock	-	-	-

Psyence Biomedical Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Psyence Biomedical (Psyence Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Psyence Biomedical (Psyence Biomedical) Headlines

From GuruFocus

Thinking about buying stock in Psyence Biomedical, Micron Technology, Conservative Broadcast Media Journalism, Qualcomm, or Cibus?

By PRNewswire • 02-12-2024